Antiphospholipid syndrome and antiphospholipid antibodies as a risk factors of ischaemic heart disease and myocardial infarction in patients with systemic lupus erythematosus;Zespół antyfosfolipidowy i przeciwciała antyfosfolipidowe jako czynniki ryzyka choroby wieńcowej i zawału serca u chorych na toczeń rumieniowaty układowy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 115, Issue 5, 2006, Pages 407-413

  Ostanek, Lidia ^a,c   Brzosko, Marek ^a   Fischer, Katarzyna ^a   Płońska, Edyta ^b  

^a Klinika Reumatologii PAM W Szczecinie   (Poland)

^b Klinika Kardiologii PAM W Szczecinie   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Ischaemic heart disease; Lupus erythematosus disseminatus; Myocardial infarction

Indexed keywords

ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CELL NUCLEUS ANTIGEN; GLUCOSE; HISTONE ANTIBODY; HOMOCYSTEINE; LIPID; LUPUS ANTICOAGULANT; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLEOSOME ANTIBODY; PHOSPHOLIPID ANTIBODY; URIC ACID;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART INFARCTION; HEART SCINTISCANNING; HUMAN; HYPERTENSION; IMMUNOLOGICAL PROCEDURES; ISCHEMIC HEART DISEASE; LABORATORY TEST; PHYSICAL EXAMINATION; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; URIC ACID BLOOD LEVEL;

EID: 33749151877     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Manger K., Manger B., Repp R. i wsp. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis. 2002; 61: 12, 1065.
2. Manzi S., Meilahn E.N., Rairie J.E. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 1: 145, 5, 408.
3. Svenungson E., Jensen-Urstad K., Heimburger M. i wsp. Risk factor for cardiovascular disease in systemic lupus eryhematosus. Circulation 2001; 104: 1887.
4. Głuszek J., Kosicka T. Powikłania sercowo-naczyniowe w toczniu rumieniowatym układowym i reumatoidalnym zapaleniu stawów. Nowe spojrzenie na stary problem. Pol Arch Med Wewn. 2005; 2: 785.
5. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res. 2004; 114: 5-6, 501.
6. Asanuma Y., Oeser A., Shintani A.K. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 18: 349, 25, 2407.
7. Lockshin M., Tenedios F., Petri M. i wsp. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003; 12: 7, 518.
8. Kattwinkel N., Villanueva A.G., Labib S.B. i wsp. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome. Ann Intern Med. 1992; 15: 116, 974.
9. Lauwerys B.R., Lambert M., Vanoverschelde J.L, Cosyns J.P., Houssiau F., A. Myocardial microangiopathy associated with antiphospholipid antibodies. Lupus. 2001; 10: 2, 123.
10. Thorburn C.M., Ward M.M. Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 9, 2519.
11. Lin C.C., Ding H.J., Chen Y.W., Wang J.J., Ho S.T., Kao A. Usefulness of technetium-99m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol. 2003; 92: 2-3, 157.
12. Sella E. M., Sato E. I., Barbieri A. Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum. 2003; 48: 11, 3168.
13. Bulkley B.H., Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975; 58: 2, 243.
14. Jensen-Urstad K., Svenungsson E., de Faire U. i wsp. Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. Lupus. 2002; 11: 744.
15. Jouhikainen T., Pohjola-Sintonen S., Stephansson E. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus. 1994; 3: 167.
16. Rahman P., Urowitz M.B., Gladman D.D., Bruce I.N., Genest J. Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol. 1999; 26: 11, 2363.
17. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med. 2005; 257: 6, 485.
18. Roman M.J., Shanker B.A., Davis A. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 18: 349, 25, 2399.
19. Sherer Y., Tenenbaum A., Praprotnik S. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology. 2001; 95: 1, 20.
20. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004; 114: 5-6, 593.
21. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res. 2004; 114: 5-6, 501.
22. Doria A., Shoenfeld Y., Wu R. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003; 62: 11, 1071.